Verastem(US:VSTM) Businesswire·2026-02-04 12:30Core Insights - Verastem Oncology has reported preliminary, unaudited net product revenues for AVMAPKI FAKZYNJA CO-PACK, amounting to approximately $17.5 million for Q4 2025 and $30.9 million for the full year 2025, reflecting the product's launch period from May to December 2025 [6][2] - The company is focused on maximizing the commercial launch of AVMAPKI FAKZYNJA CO-PACK and advancing its clinical pipeline targeting RAS/MAPK pathway-driven cancers in 2026 [4][2] Financial Update - The expected net product revenues for AVMAPKI FAKZYNJA CO-PACK are approximately $17.5 million for Q4 2025 and $30.9 million for the full year 2025 [6] - As of January 25, 2026, the company has netted $29.4 million from exercised cash warrants, with total cash, cash equivalents, and investments amounting to $205 million as of December 31, 2025 [6] - The company anticipates that the LGSOC commercial launch and development program will be self-sustaining by the second half of 2026 [6] 2026 Priorities - The company aims to maximize the adoption of AVMAPKI FAKZYNJA CO-PACK in the U.S. as the treatment of choice for KRAS-mutated recurrent low-grade serous ovarian cancer [7] - Key clinical trials include the ongoing RAMP 301 Phase 3 trial, which is fully enrolled and aims to confirm the initial indication for AVMAPKI FAKZYNJA CO-PACK [4][14] - The company plans to report topline results from the RAMP 301 trial in mid-2027 [7] Clinical Development - The ongoing RAMP 201J Phase 2 trial in Japan has shown a confirmed overall response rate (ORR) of 38% among 16 efficacy-evaluable patients, with a 57% ORR in KRAS-mutated patients [4] - The company is also advancing VS-7375, an investigational oral KRAS G12D inhibitor, with ongoing Phase 1/2 trials in various solid tumors [21][12] Product Information - AVMAPKI FAKZYNJA CO-PACK is the first FDA-approved treatment for adults with KRAS-mutated recurrent low-grade serous ovarian cancer who have received prior systemic therapy [15][14] - The combination therapy is designed to inhibit critical signaling pathways in cancer, specifically targeting the RAS/MAPK pathway [11][23]